A device designed to capture more TAVR procedural debris proves noninferior to an existing device in a large trial, but the ...

The question remains: what will it take to prove that any protection device is having a meaningful impact on stroke risk?

PROTECT H2H is the first randomized IDE trial of an embolic protection device in TAVR to meet all primary and secondary safety and efficacy endpoints, representing a significant clinical and regulator ...

Emboline's Emboliner system excels in a global trial, showing superior debris capture and procedural success in TAVR patients ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Recently published research shows a medical device may be beneficial for patients who have previously had a stroke and are planning to undergo a transcatheter aortic valve replacement, a type of heart ...

Emboline, Inc., a privately held medical technology company developing embolic protection solutions for structural heart procedures, today announced positive results from its pivotal PROTECT H2H ...

The "Embolic Protection Device Market Report, Forecast by Product, Application, Procedure, Material, Usage, End-User, Countries and Company Analysis, 2024-2032" report has been added to ...

DUBLIN, April 18, 2023 /PRNewswire/ -- The "Embolic Protection Device Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been ...